The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults. Developed by Eli Lilly, this drug offers an alternative to ...

In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The Biden administration is withdrawing a set of proposed rules aimed at expanding access to contraception that would have ...

On Dec. 20, the Wild Felid Advocacy Center of Washington announced on Facebook that highly pathogenic avian influenza, more ...

March S&P 500 E-Mini futures (ESH25) are up +0.14%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.18% this morning ahead of a holiday-shortened pre-Christmas trading session. The U.S. stock ...

Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therapeutics.